Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia

Regulatory Peptides

Volumn 185, Issue , 2013, Pages 1-8

  Lorenz, Martin ^a   Pfeiffer, Claudia ^a   Steinsträßer, Axel ^a   Becker, Reinhard H A ^a   Rütten, Hartmut ^a   Ruus, Peter ^a   Horowitz, Michael ^b  

^a Academic Hospital Frankfurt am Main Höchst   (Germany)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Gastric emptying; Glucagon like peptide 1 receptor agonist; Lixisenatide; Postprandial blood glucose; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; HEMOGLOBIN A1C; INSULIN; LIXISENATIDE; METFORMIN; OCTANOIC ACID C 13; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL MOTILITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GOOD CLINICAL PRACTICE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH EMPTYING; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84878549237     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.04.001     Document Type: Article

References (38)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
2. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
3. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011, 124:S3-S18.
4. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
5. Linnebjerg H., Park S., Kothare P.A., Trautmann M.E., Mace K., Fineman M., Wilding I., Nauck M., Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008, 151:123-129.
6. Horowitz M., Edelbroek M.A., Wishart J.M., Straathof J.W. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993, 36:857-862.
7. Jones K.L., Horowitz M., Carney B.I., Wishart J.M., Guha S., Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996, 37:1643-1648.
8. Gonlachanvit S., Hsu C.W., Boden G.H., Knight L.C., Maurer A.H., Fisher R.S., Parkman H.P. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003, 48:488-497.
9. Marathe C.S., Rayner C.K., Jones K.L., Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011, 2011:279530.
10. Horowitz M., Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol 1991, 5:371-407.
11. Rayner C.K., Samsom M., Jones K.L., Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371-381.
12. Deane A.M., Chapman M.J., Fraser R.J., Summers M.J., Zaknic A.V., Storey J.P., Jones K.L., Rayner C.K., Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010, 38:1261-1269.
13. Little T.J., Pilichiewicz A.N., Russo A., Phillips L., Jones K.L., Nauck M.A., Wishart J., Horowitz M., Feinle-Bisset C. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006, 91:1916-1923.
14. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60:1561-1565.
15. Flint A., Kapitza C., Hindsberger C., Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011, 28:213-226.
16. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
17. Ratner R.E., Rosenstock J., Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010, 27:1024-1032.
18. Kapitza C., Forst T., Coester H.C., Poitiers F., Ruus P., Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with T2DM inadequately controlled with metformin. Diabetes Obes Metab 2013, (in press). 10.1111/dom. 12076.
19. Fonseca V.A., Alvarado-Ruiz R., Raccah D., Boka G., Miossec P., Gerich J.E. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012, 35:1225-1231.
20. Pinget M., Goldenberg R., Niemoeller E., Muehlen-Bartmer I., Guo H., Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013, [in press]. 10.1111/dom.12121.
21. Bolli G., Munteanu M., Dotsenko S., Niemoeller E., Boka G., Hanefield M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Diabetologia 2011 12-16 September 2011, 54:1-542. Diabetologia, Lisbon Portugal, [Suppl 1, (Abstract 784)].
22. Ahrén B., Leguizamo Dimas A., Miossec P., Saubado S., Aronson R. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). Diabetes Care 2013, [in press]. 10.2337/dc12-2006.
23. Ratner R., Hanefield M., Shamanna P., Min K., Boka G., Miossec P., Muehlen-Bartmer I., Rosenstock J. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea±metformin (GetGoal-S). Diabetologia 2011, 54. [(Suppl 1): 1-542 (Abstract 785)].
24. Riddle M.C., Forst T., Aronson R., Sauque-Reyna L., Souhami E., Silvestre L., Ping L., Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-Week, Randomized, Placebo-Controlled Study (GetGoal-Duo 1). Diabetes Care 2013, [in press]. 10.2337/dc12-246.
25. Riddle M.C., Aronson R., Home P., Marre M., Niemoeller E., Miossec P., Ping L., Ye J., Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, [in press]. 10.2337/dc12-2454.
26. Seino Y., Min K.W., Niemoeller E., Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012 Oct, 14(10):910-917.
27. [Accessed 12 March 2013]. http://ec.europa.eu/health/documents/community-register/html/h811.htm.
28. Ghoos Y.F., Maes B.D., Geypens B.J., Mys G., Hiele M.I., Rutgeerts P.J., Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993, 104:1640-1647.
29. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
30. Woerle H.J., Neumann C., Zschau S., Tenner S., Irsigler A., Schirra J., Gerich J.E., Goke B. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007, 77:280-285.
31. 2011 Guideline for Management of PostMeal Glucose in Diabetes International Diabetes Federation 2011, http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf.
32. Node K., Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009, 8:23.
33. Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M., Knudsen L.B. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab 2012, 14:531-538.
34. Ionut V., Zheng D., Stefanovski D., Bergman R.N. Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab 2008, 295:E269-E277.
35. Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., Rungby J., Landau B.R., Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
36. Bydureon Summary of Product Characteristics Available at, [Accessed 12 March 2013]. http://ec.europa.eu/health/documents/community-register/2011/20110617103730/anx_103730_en.pdf.
37. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., Zychma M., Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
38. Thorkildsen C., Neve S., Larsen B.D., Meier E., Petersen J.S. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003, 307:490-496.